Although tolvaptan bests fluid restriction at raising plasma sodium concentration, 19% of patients experience overcorrection of sodium increases.
This titrate-up and taper-down controversy stems from concerns regarding the potential for hyperglycemia upon initiation of total parenteral nutrition (TPN) and for hypoglycemia upon discontinuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results